AbbVie Inc. (NYSE: ABBV) reported fourth quarter 2020 earnings results today. Worldwide net revenues rose 59.2% year-over-year to $13.8 billion on a reported basis. On an operational basis, sales rose 6.8%. Net earnings attributable to AbbVie were $36 million, or $0.01 per share, compared to $2.8 billion, or $1.88 per share, last year. The GAAP […]
“AbbVie Inc. (NYSE: ABBV) reported fourth quarter 2020 earnings results today. Worldwide net revenues rose 59.2% year-over-year to $13.8 billion on a reported basis. On an operational basis, sales rose 6.8%. Net earnings attributable to AbbVie were $36 million, or $0.01 per share, compared to $2.8 billion, or $1.88 per share, last year. The GAAP […]
· February 3, 2021
AbbVie Inc. (NYSE: ABBV) reported fourth quarter 2020 earnings results today.
Worldwide net revenues rose 59.2% year-over-year to $13.8 billion on a reported basis. On an operational basis, sales rose 6.8%.
Net earnings attributable to AbbVie were $36 million, or $0.01 per share, compared to $2.8 billion, or $1.88 per share, last year. The GAAP results included a non-cash charge for Skyrizi contingent consideration revaluation based on higher estimated future sales. Adjusted EPS totaled $2.92.
Both revenue and earnings surpassed market projections.
For the full year of 2021, GAAP EPS is expected to be $6.69-6.89 and adjusted EPS is expected to be $12.32-12.52.
